Physician profile
Eugene Milder
NPI 1770561722
$2,275.24
in general payments reported to CMS, 2019-2025
14 companies · $311 in 2025
The $311 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $473 · 2020: $72.40 · 2021: $436 · 2022: $484 · 2023: $116 · 2024: $383 · 2025: $311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $810.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $809.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $520.92 | 2019-2022 | |
| Genentech USA, INC. | $334.56 | 2019-2024 | Vabysmo |
| Regeneron Healthcare Solutions, INC. | $331.24 | 2019-2025 | Eylea Hd |
| Glaukos Corporation | $136.91 | 2021 | |
| Allergan, INC. | $127.62 | 2019-2020 | |
| Astellas Pharma US INC | $125.00 | 2024 | Izervay |
| Tarsus Pharmaceuticals, INC. | $120.00 | 2025 | Xdemvy |
| Notal Vision, INC. | $118.97 | 2022 | |
| Genentech, INC. | $115.93 | 2021 | |
| Abbvie INC. | $112.47 | 2023-2025 | |
| Ocular Therapeutix, INC. | $88.80 | 2019 | |
| Novartis Pharmaceuticals Corporation | $73.65 | 2019 | |
| Boston Scientific Corporation | $42.85 | 2023 | |
| Mallinckrodt Hospital Products INC. | $26.32 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Milder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.